A phase I study of RMC-035 to evaluate safety in healthy volunteers.

Trial Profile

A phase I study of RMC-035 to evaluate safety in healthy volunteers.

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs RMC 035 (Primary)
  • Indications Acute kidney injury; Preeclampsia; Radiation injuries
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Aug 2018 According to an A1M Pharma AB media release, results are expected in the first half of 2019.
    • 10 Aug 2018 According to an A1M Pharma AB media release, this study is scheduled to start later in 2018.
    • 31 Jan 2018 According to an A1M Pharma AB media release, the company has submitted an application to the Swedish Medical Products Agency to conduct a clinical phase I study in healthy volunteers.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top